|
|
News Breaks
|
November 19, 2009
|
| 09:28 EDT |  | CEPH |
| theflyonthewall.com: | Cephalon may exercise its option to acquire BDC | | On November 18, Cephalon and BioAssets Development Company, a privately held biopharmaceutical compan, agreed that all conditions establishing the effectiveness of the option have been met. As a result, the Company may exercise its option to acquire BDC at any time until the date that is sixty days after receipt of one-month patient response data from BDC’s Phase II proof of concept study with respect to etancercept for the treatment of sciatica. Within five business days of the Option Effective Date and as previously disclosed, the Company will make a $30M upfront payment to BDC. :theflyonthewall.com |
|
|
News For CEPH From The Last 14 Days Check below for free stories on CEPH the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
